HUTCHMED (China) Limited

AIM:HCM Stock Report

Market Cap: UK£2.0b

HUTCHMED (China) Future Growth

Future criteria checks 1/6

HUTCHMED (China)'s earnings are forecast to decline at 64.4% per annum while its annual revenue is expected to grow at 14.5% per year. EPS is expected to decline by 60.8% per annum. Return on equity is forecast to be 9.8% in 3 years.

Key information

-64.4%

Earnings growth rate

-60.77%

EPS growth rate

Pharmaceuticals earnings growth13.0%
Revenue growth rate14.5%
Future return on equity9.83%
Analyst coverage

Good

Last updated21 Sep 2025

Recent future growth updates

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02
Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Recent updates

Is HUTCHMED (China) (LON:HCM) Using Debt Sensibly?

Sep 22
Is HUTCHMED (China) (LON:HCM) Using Debt Sensibly?

Revenues Tell The Story For HUTCHMED (China) Limited (LON:HCM) As Its Stock Soars 31%

Jul 30
Revenues Tell The Story For HUTCHMED (China) Limited (LON:HCM) As Its Stock Soars 31%
User avatar

Late-stage Approvals And Global Expansion Will Unlock Demand

Late-stage pipeline progress, geographic expansion, and international partnerships position the company for strong, sustainable revenue and margin growth.

After Leaping 26% HUTCHMED (China) Limited (LON:HCM) Shares Are Not Flying Under The Radar

Jun 13
After Leaping 26% HUTCHMED (China) Limited (LON:HCM) Shares Are Not Flying Under The Radar

HUTCHMED (China) Limited's (LON:HCM) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors

Apr 09
HUTCHMED (China) Limited's (LON:HCM) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Dec 11
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

Oct 19
HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10
Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02
Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11
HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04
We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14
HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01
The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

Dec 18
Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Nov 23
HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Aug 24
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

AIM:HCM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027835110869021
12/31/202670268184326
12/31/202559338230923624
6/30/2025602467-60-33N/A
3/31/2025616252-39-16N/A
12/31/202463038-170N/A
9/30/2024621-2-41-23N/A
6/30/2024611-42-65-47N/A
3/31/2024724296186N/A
12/31/2023838101187219N/A
9/30/20237983695133N/A
6/30/2023757-29248N/A
3/31/2023592-195-151-110N/A
12/31/2022426-361-305-269N/A
9/30/2022414-308-276-246N/A
6/30/2022401-255-246-223N/A
3/31/2022376-235-245-227N/A
12/31/2021356-195-221-204N/A
9/30/2021317-187-169-155N/A
6/30/2021279-178-118-105N/A
3/31/2021258-151-95-83N/A
12/31/2020228-126-70-62N/A
9/30/2020221-117-72-63N/A
6/30/2020209-110-88-79N/A
3/31/2020204-102-63-54N/A
12/31/2019205-106-89-81N/A
9/30/2019205-93-86-77N/A
6/30/2019214-87-52-44N/A
3/31/2019214-83N/A-31N/A
12/31/2018214-75N/A-33N/A
9/30/2018218-72N/A-33N/A
6/30/2018217-61N/A-47N/A
3/31/2018230-39N/A-49N/A
12/31/2017241-27N/A-9N/A
9/30/2017240-7N/A-4N/A
6/30/201723813N/A1N/A
3/31/201722712N/A-4N/A
12/31/201621612N/A-10N/A
9/30/201620038N/A2N/A
6/30/2016200-8N/A-1N/A
3/31/2016189-22N/A-5N/A
12/31/2015178-35N/A-9N/A
9/30/2015168-80N/A-11N/A
6/30/2015139-66N/A-6N/A
3/31/2015113-50N/A1N/A
12/31/201487-35N/A8N/A
9/30/201472-20N/A11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCM's earnings are forecast to decline over the next 3 years (-64.4% per year).

Earnings vs Market: HCM's earnings are forecast to decline over the next 3 years (-64.4% per year).

High Growth Earnings: HCM's earnings are forecast to decline over the next 3 years.

Revenue vs Market: HCM's revenue (14.5% per year) is forecast to grow faster than the UK market (4.1% per year).

High Growth Revenue: HCM's revenue (14.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HCM's Return on Equity is forecast to be low in 3 years time (9.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/24 17:41
End of Day Share Price 2025/09/24 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 56 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish